1.上海中医药大学附属龙华医院肿瘤科(上海 200032)
郑展,男,博士,研究员,硕士研究生导师,主要从事中医药防治恶性肿瘤临床与研究工作
徐振晔,教授,博士研究生导师; E-mail:xuzhenye1947@126.com
扫 描 看 全 文
郑展,徐振晔,陆琪俊等.肺岩宁颗粒治疗男性精气两亏型中晚期肺鳞癌的临床研究[J].上海中医药杂志,2022,56(06):42-45.
ZHENG Zhan,XU Zhenye,LU Qijun,et al.Clinical study on Feiyanning Granule in treating intermediate and advanced stage lung squamous cell carcinoma of male patients with essence and qi deficiency syndrome[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(06):42-45.
郑展,徐振晔,陆琪俊等.肺岩宁颗粒治疗男性精气两亏型中晚期肺鳞癌的临床研究[J].上海中医药杂志,2022,56(06):42-45. DOI: 10.16305/j.1007-1334.2022.2110076.
ZHENG Zhan,XU Zhenye,LU Qijun,et al.Clinical study on Feiyanning Granule in treating intermediate and advanced stage lung squamous cell carcinoma of male patients with essence and qi deficiency syndrome[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(06):42-45. DOI: 10.16305/j.1007-1334.2022.2110076.
目的,2,观察肺岩宁颗粒治疗男性精气两亏型中晚期肺鳞癌的临床疗效。,方法,2,将60例男性精气两亏型中晚期肺鳞癌患者随机分为治疗组(30例)和对照组(30例),治疗组服用肺岩宁颗粒,对照组服用肺岩宁颗粒模拟剂,两组疗程均为2个月。观察临床疗效,比较中医证候积分、卡氏(KPS)评分及肿瘤标志物、免疫指标水平的变化情况。,结果,2,①治疗组疾病控制率为80.0%,对照组疾病控制率为56.7%,治疗组临床疗效优于对照组(,P,<,0.05)。②治疗前后组内比较,治疗组疲乏、咳嗽、咯血、疼痛、失眠评分减少(,P,<,0.05),对照组上述中医证候评分差异无统计学意义(,P,>,0.05);组间治疗后比较,治疗组疲乏、咳嗽、咯血、疼痛、失眠评分少于对照组(,P,<,0.05)。③治疗组KPS评分控制情况优于对照组(,P,<,0.05)。④治疗前后组内比较,治疗组癌抗原12-5(CA12-5)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞癌相关抗原(SCC)水平降低(,P,<,0.05),对照组肿瘤标志物水平差异无统计学意义(,P,>,0.05);组间治疗后比较,治疗组CA12-5、CYFRA21-1、SCC水平低于对照组(,P,<,0.05)。⑤治疗前后组内比较,两组各免疫指标差异均无统计学意义(,P,>,0.05);组间治疗后比较,治疗组NK细胞、CD4,+,水平高于对照组(,P,<,0.05)。,结论,2,肺岩宁颗粒治疗男性精气两亏型中晚期肺鳞癌疗效满意,可有效改善患者临床症状及免疫功能,提高生存质量,降低血清肿瘤标志物水平,抑制肿瘤生长。
Objective,2,To observe the clinical efficacy of Feiyanning Granule in treating the intermediate and advanced stage lung squamous cell carcinoma (LSCC) of male patients with essence and qi deficiency syndrome.,Methods,2,Sixty male patients with intermediate and advanced stage LSCC of essence and qi deficiency syndrome were randomly divided into a treatment group (,n,=30) and a control group (,n,=30). The treatment group was treated with Feiyanning Granule, while the control group was treated with Feiyanning Granule simulant. The course of treatment of both groups lasted 2 months. We observed the clinical efficacy, and compared the changes of Traditional Chinese Medicine (TCM) syndrome score, Karnofsky Performance Status (KPS) score, serum tumor markers and related immune indexes.,Results,2,①After treatment, the disease control rate of the treatment group was 80.0% and that of the control group was 56.7%. The clinical efficacy of the treatment group was better than that of the control group (,P,<,0.05). ②According to the intra-group comparison before and after treatment, the scores of fatigue, cough, hemoptysis, pain and insomnia in the treatment group decreased (,P,<,0.05), while there was no significant difference in the above-mentioned TCM syndrome scores in the control group (,P,>,0.05). After treatment, the scores of fatigue, cough, hemoptysis, pain and insomnia in the treatment group were lower than those in the control group (,P,<,0.05). ③The KPS score of the treatment group was better than that of the control group (,P,<,0.05). ④The intra-group comparison before and after treatment showed that the levels of cancer antigen 12-5 (CA12-5), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and squamous cell cancinoma associated antigen(SCC) in the treatment group decreased (,P,<,0.05); there was no significant difference in the level of tumor markers in the control group (,P,>,0.05); after treatment, the levels of CA125, CYFRA21-1 and SCC in the treatment group were lower than those in the control group (,P,<,0.05). ⑤There was no significant difference in the immune indexes between the two groups before and after treatment (,P,>,0.05); After treatment, the levels of CD4, +, and NK cells in the treatment group were higher than those in the control group (,P,<,0.05).,Conclusion,2,Feiyanning Granule is effective in the treatment of intermediate and advanced stage lung squamous cell carcinoma of male patients with essence and qi deficiency syndrome, as it can effectively improve the clinical symptoms and immune function, enhance the quality of life, reduce serum levels of tumor markers and inhibit tumor growth.
肺鳞癌中晚期肿瘤精气两亏证肺岩宁临床试验
lung squamous cell carcinomaintermediate and advanced tumoressence and qi deficiency syndromeFeiyanningclinical trial
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
KOBAYASHI-WATANABE N, SATO A, WATANABE T, et al. Functional analysis of Discoidin domain receptor2 mutation and expression in squamous cell lung cancer[J/OL]. Lung Cancer, 2017, 110: 35-41[2021-09-30]. https://pubmed.ncbi.nlm.nih.gov/28676216/https://pubmed.ncbi.nlm.nih.gov/28676216/.
贾漫漫,李纪宾,林华,等. 吸烟对男性肺癌患者组织学分型的影响及其趋势分析[J]. 中国肺癌杂志,2017, 20(8): 516-521.
SCHULER M, YANG J C, PARK K, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase Ⅲ randomized LUX-Lung 5 trial[J]. Ann Oncol, 2016, 27(3): 417-423.
HU W, LIU Y, CHEN J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer[J]. Oncotarget, 2017, 8(15): 25046-25054.
杜佳,肖何,许明芳,等. 556例非手术男性肺癌预后分析[J]. 检验医学与临床,2017, 14(7): 939-943.
XU Z Y, JIN C J, ZHOU C C, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy[J]. J Cancer Res Clin Oncol, 2011, 137(7): 1117-1122.
支修益,吴一龙,马胜林,等. 原发性肺癌诊疗规范[J]. 中国肺癌杂志,2012, 15(12): 677-688.
徐振晔,杨宇飞. 肺癌中西医综合治疗[M]. 北京:人民卫生出版社,2002: 451-456.
国家药品监督局. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002: 219-221.
THERASSE P, ARBUCK S G, EISENHAUER E A, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
王中奇,徐振晔. 益气养精法治疗中晚期肺癌的探讨[J]. 上海中医药大学学报,2002, 16(4): 30-31.
王立芳,蔡玥娇,周航,等. 肺岩宁颗粒治疗精气两亏型中晚期肺腺癌的临床研究[J]. 上海中医药杂志,2018, 52(4): 49-52.
郑展,王菊勇,徐振晔. 肺岩宁颗粒干预细胞周期G1/S检测点调控信号抗Lewis肺癌细胞增殖的研究[J]. 中国中西医结合杂志,2009, 29(11): 1018-1022.
郑展,马玥,王青,等. 顺铂诱导肺癌A549细胞保护性自噬及肺岩宁对自噬蛋白Atg5、Atg7的影响[J]. 上海中医药杂志,2018, 52(4): 77-80.
许婉,孙明瑜. 国医大师刘嘉湘以益气养阴法治疗胃癌术后经验[J]. 上海中医药杂志,2020, 54(12): 28-30.
0
浏览量
114
下载量
0
CSCD
1
CNKI被引量
关联资源
相关文章
相关作者
相关机构